Adicet Bio, Inc.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company developing allogeneic gamma delta T-cell therapies for autoimmune diseases and cancer. Its engineered, donor-derived cells are designed as “off-the-shelf” treatments, with prulacabtagene leucel (prula-cel), a CD20-targeting CAR T-cell candidate,… From the company’s description.
In fiscal 2025, Adicet Bio, Inc. reported a net loss of $116.80M. Operations used $95.25M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Adicet Bio, Inc. does
In the company’s own words
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company developing allogeneic gamma delta T-cell therapies for autoimmune diseases and cancer. Its engineered, donor-derived cells are designed as “off-the-shelf” treatments, with prulacabtagene leucel (prula-cel), a CD20-targeting CAR T-cell candidate, in Phase 1 studies for autoimmune conditions including lupus nephritis, systemic lupus erythematosus, systemic sclerosis and rheumatoid arthritis. The company is also advancing ADI-212, a gene-edited, IL-12-armored candidate targeting PSMA for metastatic castration-resistant prostate cancer; development of its ADI-270 candidate for renal cancer has been discontinued. Adicet uses a proprietary platform to activate and expand Vδ1 gamma delta T cells from unrelated donors, engineer them with CARs and manufacture them for potential use across patients. Its pipeline also includes discovery and preclinical programs for autoimmune diseases, hematological malignancies and solid tumors. The company acquired Applied Immune Technologies in 2016, adding intellectual property and establishing its wholly owned Adicet Bio Israel subsidiary. Its website is https://www.adicetbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1720580
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Adicet Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Adicet Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Adicet Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Adicet Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Adicet Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”